Localized Sinus Drug Delivery

Intersect ENT has developed the PROPEL family of dissolvable implants for chronic sinusitis patients undergoing sinus surgery; the first and only sinus surgery product backed by Level 1-A evidence which improves sinus surgery outcomes.1

Localized Sinus Drug Delivery

Intersect ENT has developed the PROPEL family of dissolvable implants for chronic sinusitis patients undergoing sinus surgery; the first and only sinus surgery product backed by Level 1-A evidence which improves sinus surgery outcomes.1

PROPEL Mometasone Furoate Logo - Localized Sinus Drug Delivery

PROPEL sinus implants are the first of a new category of products offering localized, controlled drug delivery directly to the sinus tissue. The spring-like implant is inserted by a physician to maintain the surgical opening, prop open the ethmoid sinus, and gradually deliver an advanced corticosteroid (mometasone furoate) with anti-inflammatory properties directly to the sinus lining as the implant dissolves.

The PROPEL sinus implant is intended for use in patients ≥ 18 years of age following ethmoid sinus surgery to maintain patency, thereby reducing the need for post-operative intervention such as surgical adhesion lysis and/or use of oral steroids. The PROPEL sinus implant separates mucosal tissues, provides stabilization of the middle turbinate, prevents obstruction by adhesions, and reduces edema.

PROPEL sinus implants are clinically proven to reduce post operative ethmoid interventions following surgery.1 The results show improved outcomes including improved post-operative outcomes, reducing the need for systemic steroids and additional surgical procedures, such as adhesion lysis.1

PROPEL Sinus Implant Meta-Analysis:
Safety and Effectiveness Following Ethmoid Sinus Surgery

PROPEL provides meaningful benefits to patients: PROPEL maintains the opening created during surgery by reducing post-operative scarring, inflammation, polyposis and middle turbinate lateralization. Reducing such scarring and inflammation is essential to improve long-term outcomes and reduce the need for revision surgery.2,3

Contraindications include patients with intolerance to mometasone furoate (MF) or a hypersensitivity to bioabsorbable polymers. Safety and effectiveness of the implants in pregnant or nursing females have not been studied. Risks may include, but are not limited to, pain/pressure, displacement of implant, possible side effects of intranasal MF, sinusitis, epistaxis, and infection. Rx Only.

PROPEL sinus implant vs control safety and effectiveness

PROPEL Sinus Implant Product Details

  • Indicated for the Ethmoid Sinus
  • Springlike Expansion for Mechanical Spacing
  • 23mm Nominal Length
U.S. Instructions for Use
EU Instructions for Use
PROPEL localized sinus drug delivery product image

Learn More About
PROPEL Sinus Implants

We have compiled resources to help physicians and patients better understand how the PROPEL steroid-releasing implant works to improve sinus surgery outcomes.

Physician Resources
Patient Resources

1Han JK, Marple BF, Smith TL, et al. Int Forum Allergy Rhinol. 2012; 2:271-279.
2Kennedy DW, Wright ED, Goldberg AN. Laryngoscope. 2000; 110(S94):29-31.
3Kennedy DW. Expert Review of Respiratory Medicine. 2012; 6(5):493-498.

The above-identified implants, delivery systems, and/or the use of the above-identified implants/delivery systems in a method may be covered by one or more U.S. and/or foreign patents, found at intersectent.com/patents